Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Women's Health Rheumatology Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting NCT07850349

Automated ABPI in Peripheral Arterial Disease a Pilot Study

Automated ABPI in Peripheral Arterial Disease a Pilot Study — Recruiting • Cardiology / Cardiovascular • NCT07850349.

📅 30 Sep 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT07850349
Sponsor
Hull University Teaching Hospitals NHS Trust
Start
2026-06-24
ClinicaliQ Trial Snapshot
  • Automated ABPI in Peripheral Arterial Disease a Pilot Study — Recruiting • Cardiology / Cardiovascular • NCT07850349.
  • What is being tested: The diagnostic accuracy of two automated ankle-brachial pressure index (ABPI) devices for detecting peripheral arterial disease across the full clinical spectrum, from asymptomatic PAD through symptomatic presentations including intermittent claudication of varying severity.
  • Patient eligibility overview: The study enrolls patients with suspected or confirmed PAD, stratified by disease presentation including asymptomatic disease, suspected symptomatic PAD, and symptomatic patients classified by severity using the Rutherford classification system.
Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The aim of this pilot study is to investigate the diagnostic accuracy of two automated ABPI devices across the spectrum of PAD (asymptomatic PAD, suspected symptomatic PAD [IC; including mild moderate and severe IC based on the Rutherford classification (21) and CLTI] and post-bypass surveillance). A second aim is to assess their useability and tolerability through semi-structured interviews with patients and clinicians. This means the research will be split into two workstreams.

Eligibility Snapshot
  • : Group 1: Asymptomatic * Adults aged 18 and over * At risk of PAD with ≥1 cardiovascular risk factor * No previous diagnosis of PAD * English speaking and able to understand test protocols Group 2a: Suspected PAD (intermittent claudication) * Adults aged 18 and over * Referred and booked into the nurse-led claudication clinic due to signs/symptoms in keeping with suspected intermittent claudication * English speaking and able to understand test protocols Group 2b: Suspected PAD (CLTI) * Adults aged 18 and over * Referred and booked into the vascular HOT clinic due to signs/symptoms in keeping with suspected CLTI * English speaking and able to understand test protocols Group 3: Post-bypass surveillance * Adults aged 18 and over * History of lower limb bypass surgery, enrolled in and attending the local surveillance programme * English speaking and able to understand test protocols

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Artificial intelligence (AI)-assisted echocardiography analysis and reporting to support the diagnosis and monitoring of heart failure: early-use assessment
Cardiology / Cardiovascular · 19 May 2026
AI-assisted echocardiography can support faster preliminary analysis and reporting of echo images in heart failure patients, potentially reducing reporting delays and improving…
View guideline →
Clinical Brief
Weight-loss jabs will be offered on NHS for people at risk of further heart attacks
Cardiology / Cardiovascular · BBC Health · 31 Mar 2026
GLP-1 receptor agonists (weight-loss jabs) will now be offered on NHS to over 1 million people in England at high cardiovascular risk,…
View brief →
Guideline
Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity
Cardiology / Cardiovascular · 07 May 2026
Semaglutide is recommended for adults with established cardiovascular disease and overweight/obesity to reduce major adverse cardiovascular events – consider prescribing as part…
View guideline →
Clinical Brief
Emma Barnett: Fighting Endometriosis
Cardiology / Cardiovascular · BBC Health · 01 Jun 2026
Endometriosis: Key Clinical Takeaways Endometriosis remains significantly under-recognised and under-diagnosed, with patients often experiencing prolonged diagnostic delays and disease burden that substantially…
View brief →
Guideline
Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy
Cardiology / Cardiovascular · 30 Jul 2026
Patient selection: Consider aficamten for symptomatic obstructive hypertrophic cardiomyopathy patients who remain symptomatic despite optimised standard therapy (beta-blockers, non-dihydropyridine calcium channel blockers,…
View guideline →
Guideline
Sotatercept for treating pulmonary arterial hypertension
Cardiology / Cardiovascular · 03 Jun 2026
Sotatercept is recommended as a treatment option for pulmonary arterial hypertension (PAH) in patients who meet NICE criteria; verify patient eligibility and…
View guideline →